SCHEMBL3566660

SCHEMBL3566660

Cc1cc(-c2ccc(C(F)(F)F)cc2)nc(-n2cnc(-c3cccc(S(=O)(=O)NC(C)(C)C)c3)c2)n1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KIF18A Q8NI77 1/20 0.40
ALDH1A1 P00352 1/20 0.39
HTT P42858 1/20 0.39
JAK2 O60674 1/20 0.38
PTGES2 Q9H7Z7 1/20 0.38
TLR2 O60603 1/20 0.37
TLR1 Q15399 1/20 0.37
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
KDM4E B2RXH2 1/20 0.37
NPC1 O15118 1/20 0.37
LMNA P02545 1/20 0.37
MAPT P10636 1/20 0.37
HPGD P15428 1/20 0.37
RAB9A P51151 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
CXCR2 P25025 2/20 0.36
HSD11B1 P28845 2/20 0.36
NPY5R Q15761 1/20 0.35
PFKFB3 Q16875 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3562723 0.92 KIF18A (0.41) KIF18AALDH1A1HTTJAK2PTGES2
SCHEMBL3569009 0.92 TLR2 (0.42) KIF18AHTTTLR2TLR1LMNA
SCHEMBL3566570 0.89 JAK2 (0.39) KIF18AALDH1A1JAK2MEN1KMT2A
SCHEMBL3560369 0.87 PTGS2 (0.40) PTGES2TLR2TLR1
SCHEMBL3566681 0.86 PTGES2 (0.39) ALDH1A1JAK2PTGES2MEN1KMT2A
SCHEMBL3563495 0.86 JAK2 (0.38) KIF18AALDH1A1JAK2PTGES2MEN1
SCHEMBL3569330 0.85 KIF18A (0.41) KIF18AALDH1A1HTTJAK2PTGES2
SCHEMBL3563604 0.85 KDM4E (0.43) KIF18AALDH1A1JAK2KMT2AKDM4E
SCHEMBL3561032 0.84 MAPT (0.42) KIF18AALDH1A1JAK2KMT2AKDM4E
SCHEMBL3560926 0.83 TLR2 (0.43) ALDH1A1TLR2TLR1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2468727-A1 Pyridine and pyrimidine derivatives as MGLUR2 antagonists F. Hoffmann-La Roche AG (CH) 2012-06-27 EP disclosed
US-8183262-B2 Central nervous system disorders; metabotropic glutamate receptors (mGluR); 2-(4-Pyridin-3-yl-imidazol-1-yl)-4-trifluoromethyl-6-(4-trifluoromethyl-phenyl)-pyrimidine HOFFMANN-LA ROCHE INC. (US) 2012-05-22 US disclosed
US-7642264-B2 Phenyl-substituted pyrimidine derivatives as mGluR antagonists HOFFMAN-LA ROCHE INC. (US) 2010-01-05 US disclosed
US-20090318474-A1 PYRIDINE AND PYRIMIDINE DERIVATIVES AS MGLUR 2 ANTAGONISTS GATTI MCARTHUR SILVIA 2009-12-24 US disclosed
EP-2001849-A1 PYRIDINE AND PYRIMIDINE DERIVATIVES AS MGLUR2 ANTAGONISTS F. Hoffmann-Roche AG (CH) 2008-12-17 EP disclosed
US-20070232583-A1 Pyridine and pyrimidine derivatives as mGIuR2 antagonists HOFFMANN-LA ROCHE INC. 2007-10-04 US disclosed
WO-2007110337-A1 PYRIDINE AND PYRIMIDINE DERIVATIVES AS MGLUR2 ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2007-10-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070232583-A1 Pyridine and pyrimidine derivatives as mGIuR2 antagonists P2RX2, P2RY2, P2RX1 KIF18A 3355/4885ALDH1A1 1138/4885HTT 3590/4885
US-20090318474-A1 PYRIDINE AND PYRIMIDINE DERIVATIVES AS MGLUR 2 ANTAGONISTS GRM2, GRM1, GRM3 KIF18A 3661/4885ALDH1A1 3286/4885HTT 2235/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.